Osservazione dei risultati ottenuti durante uno studio pilota, con impianto di lenti EyeMax in 11 pazienti affetti da maculopatia senile bilaterale.
Hengerer FH1, Auffarth GU2, Robbie SJ3, Yildirim TM2, Conrad-Hengerer I2.
1 Department of Ophthalmology, University of Heidelberg, Heidelberg, Germany. Electronic address: firstname.lastname@example.org.
2 Department of Ophthalmology, University of Heidelberg, Heidelberg, Germany.
3 Department of Ophthalmology, St. Thomas’ Hospital, London, United Kingdom.
2018 September; 2(9):900-905. doi: 10.1016/j.oret.2018.02.003. Epub 2018 Mar 22.
To determine the visual outcomes of the EyeMax Mono intraocular lens (IOL) technology (London Eye Hospital Pharma, London, UK), which is a foldable and injectable hydrophobic acrylic IOL implanted as an add-on solution in pseudophakic eyes with age-related macular degeneration, in a pilot study.
A prospective, interventional case series.
A total of 22 pseudophakic eyes (11 patients) with bilateral severe or intermediate dry age-related macular degeneration (AMD) (13 eyes) or stable wet AMD or disciform scarring (9 eyes) meeting the criteria for sulcal IOL implantation.
Both eyes of participating subjects underwent small-incision ciliary sulcal implantation of a hyperaspheric, soft hydrophobic acrylic intraocular lens designed to improve the quality of the retinal image in all areas of the macula ≤10° from fixation and to generate a moderate hypermetropic correction for magnification.
MAIN OUTCOME MEASURES:
The primary outcome was safety as determined by intra- and postoperative complications, raised intraocular pressure requiring medical or surgical intervention, postoperative diplopia, reduction in visual field, and loss of ≥2 lines of visual acuity. Secondary outcomes were improvements in subjective and objective visual acuity (logarithm of the minimum angle of resolution).
No intraoperative complication occurred. Elevated intraocular pressure values were measured directly after the operative procedure in 2 eyes (25 mmHg and 27 mmHg) and at the 1-week postoperative visit in 1 eye (22 mmHg) but not later. The mean postoperative spherical equivalent of refraction changed to +2.5 diopters, and all eyes had gained ≥2 lines of visual improvement (corrected distance visual acuity) by 6 months after surgery. Corrected near visual acuity as well as corrected distance visual acuity improved over time, suggesting a neuroadaptive component to improved visual function with the device. Devices were implanted bilaterally in all patients, and there were no reported symptoms of dysphotopsia or diplopia.
Safety concerns were not identified in the short-term or medium term. These results indicate the potential of the EyeMax Mono IOL to improve near and distance visual acuity in pseudophakic eyes with intermediate to severe AMD.
Copyright © 2018 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.